Abstract:Purpose: Oncolytic virus therapy has gradually become an integral approach in cancer treatment. We explored the therapeutic effects of the combination of a dual cancer-selective anti-tumor recombinant adenovirus (Ad-Apoptin-hTERTp-E1a) and cyclophosphamide on breast cancer cells.Methods: The inhibition of MCF-7 and MDA-MB-231 breast cancer cells by Ad-Apoptin-hTERTp-E1a (Ad-VT), cyclophosphamide, and Ad-VT + Cyclophosphamide was investigated using the CCK-8 assay. The combination index (CI) was calculated using CalcuSyn software to determine the best combination based on the inhibition rates of the different treatment combinations. The CCK-8 assay and crystal violet staining were used to detect the cytotoxicity of the combined Ad-VT and cyclophosphamide in breast cancer cells and breast epithelial cells. Subsequently, Hoechst staining, annexin V flow cytometry, and JC-1 staining were used to analyze the inhibitory pathway of Ad-VT plus cyclophosphamide on breast cancer cells. Cell migration and invasion of breast cancer cells were assessed using the cell-scratch and Transwell assays. The anti-tumor effects of different treatment groups in a tumor-bearing nude mouse model also were analyzed. Results: The treatment combination of Ad-VT (40 MOI) and cyclophosphamide (400 mu M) significantly inhibited MCF-7 and MDA-MB-231 cells and reduced the toxicity of cyclophosphamide in normal cells. Ad-VT primarily induced breast cancer cell apoptosis through the endogenous apoptotic pathway. Apoptosis was significantly increased after treatment with Ad-VT plus cyclophosphamide. The combination significantly inhibited the migration and invasion of MCF-7 and MDA-MB-231 cells. The in vivo experiments demonstrated that exposure to Ad-VT plus cyclophosphamide significantly inhibited tumor growth and extended the survival time of the nude mice.Conclusion: Ad-VT plus cyclophosphamide reduced toxicity and exhibited increased efficacy in treating breast cancer cells.

A comparative study of the ability of recombinant oncolytic adenovirus, doxorubicin and tamoxifen to inhibit the proliferation of breast cancer cells

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in Vitro and in Vivo

Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells

A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Ad-Apoptin-hTERTp-E1a Regulates Autophagy Through the AMPK-mTOR-eIF4F Signaling Axis to Reduce Drug Resistance of MCF-7/ADR Cells

Suppression Effect of a Dual Cancer-Specific Oncolytic Adenovirus on Luciferase-Labeled Human Melanoma Cells in Vitro and in Vivo

Inhibition of Tumor Growth by Recombinant Adenovirus Containing Human Lactoferrin Through Inducing Tumor Cell Apoptosis in Mice Bearing Emt6 Breast Cancer

Anti-Tumor Synergistic Effect Of A Dual Cancer-Specific Recombinant Adenovirus And Paclitaxel On Breast Cancer

Ad-VT causes ovarian cancer A2780 cell death via mitochondrial apoptosis and autophagy pathways

A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma

The Inhibitory Effect of Recombinant Adenovirus Rad-Mk-tnfα on Cell Growth of Breast Cancer:An in Vitro Study

Experimental Study of Breast Cancer Treatment with Recombinant EGFR Antisense Adenovirus

Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo

Influence of TK adenovirus vector regulated by hypoxia and radiation on the growth and apoptosis of breast cancer cells

Oncolytic Adenovirus Encoding Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Inhibits the Growth and Metastasis of Triple-Negative Breast Cancer

Antitumor Effects of a Dual Cancer-Specific Oncolytic Adenovirus on Colorectal Cancer in Vitro and in Vivo

Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research

A Conditionally Replicating Adenovirus CNHK500 for the Treatment of Breast Cancer

Synergistic Antitumor Efficacy of Oncolytic Adenovirus Combined with Chemotherapy